IRDAI (Insurance Products) Regulations 2024: The Single Rulebook Behind Modern Life, Health and Motor Policies

Until March 2024, a single life or health policy in India had to satisfy several separate IRDAI product rulebooks at once. An endowment plan answered to one regulation, a unit-linked plan to another, a health cover to a third, and the surrender-value floor to yet another. The IRDAI (Insurance Products) Regulations, 2024 ended that fragmentation by collapsing six earlier product regulations into a single, principle-based code notified during the regulator's 2024 consolidation drive.

This single rulebook now sits behind almost every retail policy sold today, from a Rs 1 crore term plan to a Rs 5 lakh family-floater health cover. It is also the parent regulation for the three Master Circulars on Life, Health and General Insurance Products that IRDAI issued through 2024. If you have bought, renewed or surrendered any policy since 2024, its provisions have shaped your contract. This deep dive explains what changed, the worked maths behind surrender values, and the wording traps that still decide whether a claim is paid.

The Rule / Product

The IRDAI (Insurance Products) Regulations, 2024 were notified in March 2024 as part of the regulator's wider 2024 revamp, which compressed dozens of legacy regulations into a smaller set of principle-based frameworks. Rather than prescribe every product feature line by line, the 2024 regulations set out broad policyholder-protection principles and delegate the detail to Master Circulars that IRDAI can update without a fresh legislative process.

Six earlier product regulations were merged into this one code. In substance they covered non-linked (traditional) life products, unit-linked life products, health insurance products, micro-insurance, minimum annuity and benefit norms, and the acquisition of surrender and paid-up values. Bringing these six domains under one regulation means an insurer designing, say, a participating endowment with a health rider no longer juggles four separate rulebooks; it works to one consolidated standard published on irdai.gov.in.

The most structural change introduced by the 2024 regulations is the Product Management Committee (PMC). Every insurer must now route each new product, and every major revision, through a board-constituted PMC that signs off on the product's risk, pricing assumptions and policyholder-fairness features before launch. This shifts accountability inside the company: the 2024 framework expects the PMC, not just the appointed actuary, to certify that a product is suitable and that its disclosures are clear.

The 2024 regulations also hard-wire policyholder-centric features that earlier rules treated as good practice. These include clearer benefit illustrations, simpler surrender mechanics, and stronger guardrails around riders and add-ons. The companion 30-day free-look window, under which you can cancel almost any policy and recover your premium net of limited charges, sits alongside this framework. For the mechanics of that cancellation right, see our free-look period glossary entry.

A further design choice in the 2024 regulations is that they are deliberately technology-neutral and update-friendly. By holding the detailed product norms in Master Circulars rather than in the regulation itself, IRDAI can revise a single circular when, for example, a new health benefit becomes standard, without reopening the parent code. The three Master Circulars published in 2024, covering Life, Health and General Insurance products respectively, are the operational layer where most buyer-facing detail now lives, and they all draw their authority from this one 2024 regulation.

Why It Matters

For a buyer, the practical value of the 2024 regulations is consistency. Because one principle-based code now governs the sum assured, surrender terms and disclosure standards across product classes, two policies from different insurers are easier to compare than they were before March 2024. When you run figures through our term insurance premium calculator, the underlying product is built to a common rulebook, which makes a like-for-like comparison more meaningful.

The Product Management Committee requirement matters because it moves quality control upstream. Under the pre-2024 regime, an unsuitable feature or an opaque charge structure was often caught only after complaints reached IRDAI. From 2024, the PMC must vet those risks before the product reaches the market, reducing the chance that a mis-designed plan is ever sold. That is a meaningful protection in a market where a 20-year or 30-year contract locks the buyer in for decades.

The surrender-value reforms carried into the 2024 framework matter most in rupee terms. Traditional savings policies have long been criticised because early exit returned very little to the policyholder. The consolidated rules preserve a minimum guaranteed surrender value floor and push insurers to set the special surrender value closer to the policy's true asset share, so that a buyer who exits in year five is not penalised as harshly as before. We unpack the numbers in the next section, and you can read the concept in plain English in our surrender value glossary entry.

Worked Numbers

Surrender value is where the 2024 framework becomes tangible. Suppose Anjali buys a 20-year participating endowment with an annual premium of Rs 50,000. She pays for three full years, contributing Rs 1,50,000 in total, and then needs to exit in policy year three. The guaranteed surrender value (GSV) is the regulatory floor below which the insurer cannot pay. The long-standing GSV schedule, preserved under the 2024 rules, expresses this as a percentage of total premiums paid.

So if Anjali surrenders in year three, the GSV floor is 30% of Rs 1,50,000, which equals Rs 45,000. Had she paid five years (Rs 2,50,000 total) and surrendered in year five, the floor would be 50% of Rs 2,50,000, or Rs 1,25,000. These are minimums: the special surrender value (SSV), which the 2024 framework wants set near the policy's accumulated asset share, is typically higher than the GSV, especially in the middle years of a long contract. The key takeaway is that exiting in year one returns nothing, so a traditional policy should only be bought if the buyer can sustain premiums for the long term.

The second place numbers bite is tax. Insurance premiums and payouts interact with three sections of the Income-tax Act, and all three deductions sit in the old tax regime only. The table below summarises the position for FY 2025-26.

Take Ravi, aged 40, in the old regime. He pays Rs 22,000 a year for a family-floater health policy and claims it in full under Section 80D, within the Rs 25,000 ceiling for those below 60, as set out on incometax.gov.in. He separately pays a Rs 12,000 term-plan premium, which counts toward his Rs 1,50,000 Section 80C limit. To size the health cover before buying, he can model premiums on our health insurance premium calculator.

The payout side is governed by Section 10(10D). For a life policy issued after 1 April 2012, maturity proceeds are exempt only if the annual premium does not exceed 10% of the sum assured. So a Rs 1 crore term plan with a Rs 25,000 premium clears the test comfortably, because Rs 25,000 is just 0.25% of the Rs 1 crore sum assured. For unit-linked plans issued on or after 1 February 2021, the 10(10D) exemption is additionally lost where aggregate annual premiums across ULIPs exceed Rs 2,50,000. If you are weighing a ULIP against a mutual fund on these terms, our ULIP versus mutual fund calculator lays out the trade-off.

Pitfalls

A consolidated rulebook does not erase the wording traps that decide claims. The first is the health sub-limit. A policy may advertise a Rs 5 lakh sum insured yet cap a specific procedure, say cataract surgery, at Rs 40,000 per eye, leaving the balance to the policyholder. The 2024 disclosure standards require these caps to be stated clearly, but they remain legal, so the headline figure can overstate real protection. Always read the schedule against our sub-limit glossary entry before assuming the full sum insured applies.

The second trap is the room-rent cap. Where a policy limits the eligible room to, say, 1% of the sum insured per day, a Rs 5 lakh cover allows only a Rs 5,000-a-day room. Choose a costlier room and many policies apply proportionate deduction across the entire bill, not just the room charge, which can shrink a Rs 3 lakh claim by tens of thousands of rupees. The arithmetic of this trap is severe enough that it deserves its own check before you buy.

A worked illustration of the room-rent trap makes the point. Suppose a Rs 5 lakh policy caps the room at 1% of the sum insured, that is Rs 5,000 a day, and the patient occupies a Rs 10,000-a-day room. Because the actual room cost is double the eligible limit, a proportionate-deduction clause can pay only half of every associated charge, so a Rs 3 lakh hospital bill may settle at roughly Rs 1.5 lakh, leaving Rs 1.5 lakh with the patient even though the sum insured was never exhausted. This is why the room category, not just the sum insured, should be checked before buying.

The third is the pre-existing disease (PED) waiting period. Conditions you already have when the policy starts are typically excluded for a defined waiting period, commonly up to 36 to 48 months depending on the contract. A claim filed for a PED inside that window is rejectable even though the policy is fully paid. Disclose every condition at proposal stage, because non-disclosure is a separate ground for repudiation under the pre-existing disease rules. The fourth common trap is co-pay, a fixed percentage of every admissible claim that you must bear, which is widespread on senior-citizen policies and quietly reduces every settlement.

FAQ

What is the IRDAI (Insurance Products) Regulations, 2024?

It is a single, principle-based regulation notified in March 2024 that merged six earlier IRDAI product regulations covering traditional life, unit-linked, health, micro-insurance, annuity and surrender-value rules into one framework. It is the parent regulation for the 2024 Master Circulars on Life, Health and General Insurance Products.

What is a Product Management Committee?

The 2024 regulations require every insurer to set up a board-constituted Product Management Committee that signs off on each new product's risk, pricing and policyholder-fairness features before it can be launched. It moves quality control upstream, so that unsuitable features are caught before sale rather than after complaints.

How is the guaranteed surrender value calculated?

The guaranteed surrender value is a percentage of total premiums paid. The schedule preserved under the 2024 rules pays nil in year one, 30% if you surrender in years two to three, 50% in years four to seven, and up to 90% in the final two policy years. On Rs 1,50,000 paid over three years, the floor is 30%, or Rs 45,000.

Are insurance premiums tax-deductible in the new regime?

No. Section 80C for life premium and Section 80D for health premium are available only in the old tax regime for FY 2025-26. In the new regime these deductions do not apply, so the tax benefit of buying insurance accrues only to old-regime taxpayers.

Does the 2024 regulation change my free-look rights?

The 30-day free-look window lets you cancel almost any policy and recover your premium net of limited charges. It operates alongside the 2024 product framework as a core policyholder protection. See our free-look period glossary entry for the exact mechanics and deductions.

Why does a Rs 5 lakh health policy sometimes pay much less?

Because of sub-limits, room-rent caps and co-pay. A sub-limit caps a specific procedure, a room-rent cap can trigger proportionate deduction across the whole bill, and co-pay makes you bear a fixed percentage of every claim. The Rs 5 lakh figure is the ceiling, not a guarantee of full reimbursement.

Can I still claim for a pre-existing disease?

Yes, but only after the policy's pre-existing disease waiting period ends, which commonly runs up to 36 to 48 months. Claims filed within that window for a declared PED are rejectable, and any non-disclosure at proposal stage is a separate ground for repudiation.